TFS HealthScience, a Sweden-based global contract research organisation, announced Monday that it is expanding into Israel to improve its offerings and geographic reach to support increasing customer demand.

The development includes a formalised agreement with the former external partner of TFS HealthScience in the Middle East, GCP Clinical Studies (GCP), Israel's leading contract research organisation (CRO), and clinical research training centre.

This agreement will further grow TFS HealthScience's expertise in the specialty therapeutic areas of ophthalmology, oncology and haematology, dermatology, immunology and inflammatory disease, and internal medicine and neuroscience.

Luke Gill, head of Clinical Development Solutions at TFS HealthScience, said, '2023 continues to be a year of growth for the company as we announce our formal expansion into Israel. We are confident that this expansion will bring immense value to our clients and ultimately support the development of more lifesaving therapies.'